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Background
HIV-1's propensity to mutate is echoed in its many muta-
tional pathways of escape from anti-retroviral, antibody
and Cytotoxic T Lymphocyte (CTL) pressures. A successful
vaccine must control a growing variety of strains.
Methods
We proposed a CTL-based 'Conserved Element' (CE)-vac-
cine exclusively composed of nearly invariant viral seg-
ments. We reason that an efficacious vaccine must elicit
responses toward HIV-1 segments that cannot mutate
without severely compromising viral viability, and must
not elicit responses against variable, immunodominant
'decoys'. Based on known HIV-1 M-group viral sequences,
we designed a Gag-p24 CE-vaccine composed of 7 seg-
ments at least 12 amino acids (AA) in length. To clarify the
relationship between sequence conservation and viral fit-
ness, we created viruses encoding AA substitutions at sites
differentially conserved among HIV-1 strains, including
CTL escape sites.
Results
Six mutants were engineered in the Gag-p24 'Center-Of-
Tree' (COT) HIV-1-B protein of a chimeric NL4-3 virus.
Mutated sites were conserved in 50 to 100% of known
group M sequences. While mutations to the 2nd most-fre-
quent AA at 5 different sites resulted in functional viruses,
a substitution at a site conserved in 100% of known
viruses yielded no virus production, possibly due to a
defect in particle formation. Viral fitness was assessed by
dual infections with the mutated and the original Gag-
p24 COT HIV-1-B viruses. Growth competition assays
showed varying fitness levels among mutants: some sub-
stitutions exacted a fitness cost to the virus while the HLA-
associated G357S substitution at a toggle site did not
impair viral fitness. Interestingly, the G357S mutation is a
CTL escape mutation in the B*0702-restricted epitope
GPGHKARVL and was found in 20% of HIV-1-B and 49%
of HIV-1-C sequences.
Conclusion
Our data better define the interrelations between HIV-1
mutations, CTL responses and viral fitness in Gag-p24 and
allow us to delineate longer HIV-1 segments for our CE-
vaccine construct.
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